CD16+ monocytes in patients with cancer

Spontaneous elevation and pharmacologic induction by recombinant human macrophage colony-stimulating factor

M. N. Saleh, S. J. Goldman, A. F. LoBuglio, A. C. Beall, H. Sabio, M. C. McCord, L. Minasian, R. K. Alpaugh, L. M. Weiner, David H Munn

Research output: Contribution to journalArticle

122 Citations (Scopus)

Abstract

The small subset of circulating monocytes that express the maturation- associated CD16 antigen has recently been reported to be elevated in patients with bacterial sepsis. We now show that this novel CD16+ monocyte population is also spontaneously expanded in patients with cancer. We studied 14 patients with metastatic gastrointestinal carcinoma enrolled in a clinical trial of recombinant human macrophage colony-stimulating factor (rhMCSF) plus monoclonal antibody D612. We found that before any cytokine treatment, 12 of 14 patients constitutively displayed significant elevations in both the percentage and the absolute number of CD16+ monocytes, as compared with both normal subjects and ill patients with elevated monocyte counts but without malignancy. CD16+ monocytes accounted for 46% ± 22% of total monocytes in the patients with cancer versus 5% ± 3% for controls (P < .01). The increase was not attributable to infection or intercurrent illness and appeared to be associated with the underlying malignancy itself. A similar spontaneous elevation of CD16+ monocytes was observed in 35 of 44 additional patients diagnosed with a variety of other solid tumors. When patients with gastrointestinal carcinoma were treated with rhMCSF, there was a marked further increase in the percentage of CD16+ monocytes (to 83% ± 11%), as well as in the absolute number of CD16+ cells and the level of CD16 antigen expression. In every case, the patients with cancer showed a greater CD16+ monocyte response than the maximal response obtained in normal volunteer subjects treated with a similar regimen of rhMCSF (n = 5, P < .001), suggesting that the presence of malignancy primed patients for enhanced responsiveness to rhMCSF. We hypothesize that spontaneous expansion of the CD16+ monocyte population may represent a novel biologic marker for a widespread and previously unsuspected host immune response to malignancy.

Original languageEnglish (US)
Pages (from-to)2910-2917
Number of pages8
JournalBlood
Volume85
Issue number10
StatePublished - Jan 1 1995

Fingerprint

Macrophage Colony-Stimulating Factor
Monocytes
IgG Receptors
Neoplasms
Tumors
Monoclonal Antibodies
Cytokines
Carcinoma
Population
Sepsis
Healthy Volunteers
Cell Count
Biomarkers
Clinical Trials

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Saleh, M. N., Goldman, S. J., LoBuglio, A. F., Beall, A. C., Sabio, H., McCord, M. C., ... Munn, D. H. (1995). CD16+ monocytes in patients with cancer: Spontaneous elevation and pharmacologic induction by recombinant human macrophage colony-stimulating factor. Blood, 85(10), 2910-2917.

CD16+ monocytes in patients with cancer : Spontaneous elevation and pharmacologic induction by recombinant human macrophage colony-stimulating factor. / Saleh, M. N.; Goldman, S. J.; LoBuglio, A. F.; Beall, A. C.; Sabio, H.; McCord, M. C.; Minasian, L.; Alpaugh, R. K.; Weiner, L. M.; Munn, David H.

In: Blood, Vol. 85, No. 10, 01.01.1995, p. 2910-2917.

Research output: Contribution to journalArticle

Saleh, MN, Goldman, SJ, LoBuglio, AF, Beall, AC, Sabio, H, McCord, MC, Minasian, L, Alpaugh, RK, Weiner, LM & Munn, DH 1995, 'CD16+ monocytes in patients with cancer: Spontaneous elevation and pharmacologic induction by recombinant human macrophage colony-stimulating factor', Blood, vol. 85, no. 10, pp. 2910-2917.
Saleh MN, Goldman SJ, LoBuglio AF, Beall AC, Sabio H, McCord MC et al. CD16+ monocytes in patients with cancer: Spontaneous elevation and pharmacologic induction by recombinant human macrophage colony-stimulating factor. Blood. 1995 Jan 1;85(10):2910-2917.
Saleh, M. N. ; Goldman, S. J. ; LoBuglio, A. F. ; Beall, A. C. ; Sabio, H. ; McCord, M. C. ; Minasian, L. ; Alpaugh, R. K. ; Weiner, L. M. ; Munn, David H. / CD16+ monocytes in patients with cancer : Spontaneous elevation and pharmacologic induction by recombinant human macrophage colony-stimulating factor. In: Blood. 1995 ; Vol. 85, No. 10. pp. 2910-2917.
@article{361c42bec4524297bb5ce8a92c51d813,
title = "CD16+ monocytes in patients with cancer: Spontaneous elevation and pharmacologic induction by recombinant human macrophage colony-stimulating factor",
abstract = "The small subset of circulating monocytes that express the maturation- associated CD16 antigen has recently been reported to be elevated in patients with bacterial sepsis. We now show that this novel CD16+ monocyte population is also spontaneously expanded in patients with cancer. We studied 14 patients with metastatic gastrointestinal carcinoma enrolled in a clinical trial of recombinant human macrophage colony-stimulating factor (rhMCSF) plus monoclonal antibody D612. We found that before any cytokine treatment, 12 of 14 patients constitutively displayed significant elevations in both the percentage and the absolute number of CD16+ monocytes, as compared with both normal subjects and ill patients with elevated monocyte counts but without malignancy. CD16+ monocytes accounted for 46{\%} ± 22{\%} of total monocytes in the patients with cancer versus 5{\%} ± 3{\%} for controls (P < .01). The increase was not attributable to infection or intercurrent illness and appeared to be associated with the underlying malignancy itself. A similar spontaneous elevation of CD16+ monocytes was observed in 35 of 44 additional patients diagnosed with a variety of other solid tumors. When patients with gastrointestinal carcinoma were treated with rhMCSF, there was a marked further increase in the percentage of CD16+ monocytes (to 83{\%} ± 11{\%}), as well as in the absolute number of CD16+ cells and the level of CD16 antigen expression. In every case, the patients with cancer showed a greater CD16+ monocyte response than the maximal response obtained in normal volunteer subjects treated with a similar regimen of rhMCSF (n = 5, P < .001), suggesting that the presence of malignancy primed patients for enhanced responsiveness to rhMCSF. We hypothesize that spontaneous expansion of the CD16+ monocyte population may represent a novel biologic marker for a widespread and previously unsuspected host immune response to malignancy.",
author = "Saleh, {M. N.} and Goldman, {S. J.} and LoBuglio, {A. F.} and Beall, {A. C.} and H. Sabio and McCord, {M. C.} and L. Minasian and Alpaugh, {R. K.} and Weiner, {L. M.} and Munn, {David H}",
year = "1995",
month = "1",
day = "1",
language = "English (US)",
volume = "85",
pages = "2910--2917",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "10",

}

TY - JOUR

T1 - CD16+ monocytes in patients with cancer

T2 - Spontaneous elevation and pharmacologic induction by recombinant human macrophage colony-stimulating factor

AU - Saleh, M. N.

AU - Goldman, S. J.

AU - LoBuglio, A. F.

AU - Beall, A. C.

AU - Sabio, H.

AU - McCord, M. C.

AU - Minasian, L.

AU - Alpaugh, R. K.

AU - Weiner, L. M.

AU - Munn, David H

PY - 1995/1/1

Y1 - 1995/1/1

N2 - The small subset of circulating monocytes that express the maturation- associated CD16 antigen has recently been reported to be elevated in patients with bacterial sepsis. We now show that this novel CD16+ monocyte population is also spontaneously expanded in patients with cancer. We studied 14 patients with metastatic gastrointestinal carcinoma enrolled in a clinical trial of recombinant human macrophage colony-stimulating factor (rhMCSF) plus monoclonal antibody D612. We found that before any cytokine treatment, 12 of 14 patients constitutively displayed significant elevations in both the percentage and the absolute number of CD16+ monocytes, as compared with both normal subjects and ill patients with elevated monocyte counts but without malignancy. CD16+ monocytes accounted for 46% ± 22% of total monocytes in the patients with cancer versus 5% ± 3% for controls (P < .01). The increase was not attributable to infection or intercurrent illness and appeared to be associated with the underlying malignancy itself. A similar spontaneous elevation of CD16+ monocytes was observed in 35 of 44 additional patients diagnosed with a variety of other solid tumors. When patients with gastrointestinal carcinoma were treated with rhMCSF, there was a marked further increase in the percentage of CD16+ monocytes (to 83% ± 11%), as well as in the absolute number of CD16+ cells and the level of CD16 antigen expression. In every case, the patients with cancer showed a greater CD16+ monocyte response than the maximal response obtained in normal volunteer subjects treated with a similar regimen of rhMCSF (n = 5, P < .001), suggesting that the presence of malignancy primed patients for enhanced responsiveness to rhMCSF. We hypothesize that spontaneous expansion of the CD16+ monocyte population may represent a novel biologic marker for a widespread and previously unsuspected host immune response to malignancy.

AB - The small subset of circulating monocytes that express the maturation- associated CD16 antigen has recently been reported to be elevated in patients with bacterial sepsis. We now show that this novel CD16+ monocyte population is also spontaneously expanded in patients with cancer. We studied 14 patients with metastatic gastrointestinal carcinoma enrolled in a clinical trial of recombinant human macrophage colony-stimulating factor (rhMCSF) plus monoclonal antibody D612. We found that before any cytokine treatment, 12 of 14 patients constitutively displayed significant elevations in both the percentage and the absolute number of CD16+ monocytes, as compared with both normal subjects and ill patients with elevated monocyte counts but without malignancy. CD16+ monocytes accounted for 46% ± 22% of total monocytes in the patients with cancer versus 5% ± 3% for controls (P < .01). The increase was not attributable to infection or intercurrent illness and appeared to be associated with the underlying malignancy itself. A similar spontaneous elevation of CD16+ monocytes was observed in 35 of 44 additional patients diagnosed with a variety of other solid tumors. When patients with gastrointestinal carcinoma were treated with rhMCSF, there was a marked further increase in the percentage of CD16+ monocytes (to 83% ± 11%), as well as in the absolute number of CD16+ cells and the level of CD16 antigen expression. In every case, the patients with cancer showed a greater CD16+ monocyte response than the maximal response obtained in normal volunteer subjects treated with a similar regimen of rhMCSF (n = 5, P < .001), suggesting that the presence of malignancy primed patients for enhanced responsiveness to rhMCSF. We hypothesize that spontaneous expansion of the CD16+ monocyte population may represent a novel biologic marker for a widespread and previously unsuspected host immune response to malignancy.

UR - http://www.scopus.com/inward/record.url?scp=0029029368&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029029368&partnerID=8YFLogxK

M3 - Article

VL - 85

SP - 2910

EP - 2917

JO - Blood

JF - Blood

SN - 0006-4971

IS - 10

ER -